Pulmonary Arterial Hypertension: 68-Market Analysis and Sales Forecast

Description

List of Tables

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market.

Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034.

The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.

Scope

This publication is an expanded version of the Excel model containing the patient-based forecast sales for PAH, covered in GlobalData's report "Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034", published in June 2025.
In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC318PIDR-68M

List of Tables

List of Figures

1 Executive Summary

1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation

2 Appendix

2.1 Abbreviations
2.2 Methodology
- 2.2.1 Patient-based forecast methodology
- 2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders and payers interviewed for this report
- 2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
- 2.5.1 Therapy Area Director
- 2.5.2 Vice President of Disease Intelligence and Epidemiology
- 2.5.3 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC318PIDR-68M

List of Table

List of Tables

Table 1: PAH market size across the 68M - 7MM versus 61M
Table 2: PAH market size across the 68M - by geographical region
Table 3: PAH, key events occurring in the 7MM driving forecast trajectory in the 68M
Table 4: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: PAH market size across the 68M - 7MM versus 61M
Figure 2: PAH market size across the 68M - by geographical region

Pulmonary Arterial Hypertension: 68-Market Analysis and Sales Forecast

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Executive Summary

2 Appendix

List of Table

List of Tables

List of Figure

List of Figures